
    
      Four treatment arms are planned.

        -  GEMVIN: gemcitabine 1000 mg/m2 and vinorelbine 25 mg/m2 on days 1 & 8, every 21 days

        -  GEMCAR: gemcitabine 1000 on days 1 & 8 and carboplatin AUC 3.5 or 4 or 4.5 on day 1,
           every 21 days

        -  GEMCIS: gemcitabine 1000 mg/m2 on days 1 & 8 and cisplatin 50 or 60 or 70 mg/m2 on day
           1, every 21 days

        -  GEMETO: gemcitabine 1000 mg/m2 on days 1 & 8 and etoposide 60 or 70 or 80 mg/m2 on days
           1,2,3 every 21 days

      For the study of the GEMVIN combination a two-stage minimax flexible design will be applied.
      For the remaining 3 combinations (GEMCAR, GEMCIS, GEMETO) a phase 1/2 design aimed at looking
      for optimal dose within a Bayesian framework will be applied.
    
  